Safe Pregnancy Confirmed in Autoimmune Disease Patients After CAR-T Therapy, Remission Maintained Despite Discontinuation of Immunosuppressants
Background
Severe autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), which commonly affect women of childbearing age, pose life-threatening risks to both mother and fetus during pregnancy and childbirth. Sudden hormonal changes caused by pregnancy can exacerbate the disease, and the potent immunosuppressants used by patients carry the risk of causing fetal malformations. As a result, patients have had to take the risky gamble of discontinuing treatment to become pregnant. While previous academic approaches have attempted to manage the situation by fine-tuning immunosuppressant dosages, there have been limitations in achieving complete disease control. A fundamental solution to ensure maternal safety is urgently needed. Recently, chimeric antigen receptor T-cell (CAR-T) therapy has gained attention as a potential solution to reset the patient's immune system. However, there have been no clinical studies analyzing whether patients who have undergone CAR-T therapy can safely maintain pregnancy.
Key Findings
This study, published in the New England Journal of Medicine (NEJM) and led by Professor Georg Schett and his team at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), is the first worldwide to comprehensively analyze pregnancy cases in autoimmune disease patients following CAR-T therapy. The research team tracked 14 pregnancy cases in 13 women who had received CD19-targeted CAR-T cell therapy at medical institutions in Germany, Belgium, China, and the United States. The patients had previously suffered from lupus, systemic sclerosis, and inflammatory myopathy. After entering a long-term remission phase post-treatment, they planned pregnancies, all of which resulted in natural conception.
The results are highly encouraging. Eight of the observed pregnancies resulted in the birth of healthy babies, and the remaining six pregnancies are progressing smoothly without complications. No patients experienced a relapse of their autoimmune disease during pregnancy. Patients maintained a stable remission state without taking any immunosuppressants during pregnancy or after childbirth. The babies' health was also excellent, with normal birth weights and physical development levels. Neonatal immune analysis showed that B-cell counts and immunoglobulin (Ig) concentrations developed appropriately for their age. Notably, no evidence of placental transfer of CAR-T cells was found in detailed examinations of umbilical cord blood, placental tissue, and neonatal blood.
Significance and Outlook
This study marks a milestone in demonstrating the paradigm shift in autoimmune disease treatment from mere symptom relief to fundamental healing through immune system resetting. The success of pregnancy was proven through the process of eliminating abnormal B-cells and allowing healthy B-cells to regenerate following CAR-T therapy. In particular, the empirical data showing that long-term immune remission and safe childbirth are possible without medication offer new hope for women of childbearing age with autoimmune diseases.
However, further research is required for full clinical adoption. The number of analyzed patients (13) is relatively small, and the observation period is not yet long enough. It is also essential to investigate the long-term effects of lymphocyte-depleting chemotherapy, performed before CAR-T cell administration, on ovarian function. Therefore, large-scale long-term follow-up studies and the development of systematic reproductive medicine guidelines are expected to be conducted in parallel to firmly establish this as a standard treatment.
New England Journal of Medicine, Volume 395, Issue 8, Page 821-824, August 20/27, 2026.
This study has the potential to dramatically change the paradigm of pregnancy planning for patients with severe lupus in real-world clinical settings. In the past, women of childbearing age who wished to become pregnant had to discontinue immunosuppressants such as mycophenolate mofetil, which are teratogenic, and had to accept the risks of nephritis exacerbation or preeclampsia. However, if a scenario involving rapid cellular therapy to reset the immune system is introduced, the situation changes. Patients could undergo fertility preservation treatment before therapy, receive a single dose of CAR-T cells, confirm normal B-cell regeneration and complete remission several months later, and then safely plan natural conception. A pathway would open in which both mother and fetus can be delivered safely without drug exposure, under the collaborative care of rheumatology and obstetrics and gynecology. The pharmaceutical industry would also gain an opportunity to expand the CAR-T therapy field, which has been focused on oncology, to a younger population of autoimmune disease patients. It is expected that competition to develop customized therapies combining long-term safety and fertility preservation technologies will intensify.